$150M from Health Canada for Marathon of Hope Cancer CentresI doubt Dr. Lilge's R&D qualifies for that. But I wonder if this one could:
Theralase® Anti-Cancer Technology Shows Promise for Esophageal Cancer Using Targeted Molecular Delivery System
Theralase® Affiliated Researchers Present New Data that Demonstrates the Application of Theralase’s Lead Photo Dynamic Compound, TLD-1433, in the Destruction of Gastrointestinal Dysplasia and Esophageal Cancer.
Toronto, Ontario – October 9, 2018
Dr. Norman Marcon, MD, FRCP, Professor of Medicine in University of Toronto, Chief of Gastroenterology for St. Michael’s Hospital, Toronto, Ontario stated, “This research was inspired by Theralase’s research into the role of the human glycoprotein Transferrin (“Tf”) and its associated cellular membrane Transferrin Receptor (“TfR”) CD71, that according to previous Theralase® research is responsible for the targeted uptake of Theralase’s lead PDC, TLD-1433, by cancer cells. The aim of our research was to characterize CD71 expression in human samples of esophageal carcinomas and their precursor lesions. Remarkably, moderate to strong CD71 staining was seen almost universally (97.2%) in both SCC and adenocarcinoma. There was a significantly stronger expression of CD71 in HGD and carcinomas versus LGD and normal squamous mucosa tissues (p <0.02). This research is exciting as we now have a way to distinguish between LGD and HGD lesions. Moreover, CD71 is an important target for Rutherrin® (TLD-1433 combined with transferrin) and hence the development of an effective, targeted and highly personalised PDT destruction of HGD precursor lesions and cancers of the esophagus. This latest research was presented and well received at the annual Canadian Academy of Pathology Meeting held in Quebec City, Quebec, Canada from July 7 to 10, 2018. Our therapeutic endoscopy group is looking forward to continuing our research with Theralase® to clinically evaluate this technology in a Phase Ib clinical study aimed at the destruction of esophageal cancer.” _____________
7/11/2019 "The Marathon of Hope Cancer Centres network will accelerate the adoption of more effective precision medicine cancer therapies through new approaches to capture, share, and learn from molecular, imaging and patient-specific big data. Only a concerted, huge push from all us within a collaborative Marathon of Hope network will help us achieve this."
An artificial intelligence (AI) platform and collaborative approach will link researches across Canada to share and analyze enormous amounts of genomic and clinical data, and apply new technologies such as genomics, advanced imaging, big data and artificial intelligence to find new and better ways to treat cancer patients.
The hope is that this level of cellular and molecular precision will help decide which treatments a patient's tumour responds best to, sparing a patient from undergoing ineffective ones.
Specifically, this approach will help scientists tackle the vexing challenges of sensitivity and resistance to treatment by understanding the constantly changing molecular and cellular features of a tumour and its microenvironment.
Five regional consortia, representing cancer research and care institutions in British Columbia, Ontario, Quebec, the Prairies and Atlantic Canada, are expected to participate in the network once fully operational.
A key network deliverable is the creation of a 15,000 high-quality sharable dataset of cancer cases completed by 2023.